Evaluation the Diagnostic Value of CXCL-13 & anti-CarP with RF & ACCP

The study revealed a highly significant difference of CXCL13 Anti-CarP Anti-CCP and RF levels between RA patients and controls at p value =0.000. CXCL13 demonstrated good specificity (83%) and high sensitivity (93%) for RA patients while Anti-CarP antibodies demonstrated low sensitivity(39%) and high specificity(98%) for diagnosis of RA. Patients with RA have positivity of 71.7% and 36.7% for RF and Anti-CarP respectively while healthy group have 11.7% and 1.7% respectively. The serum levels of CXCL13 anti-CarP and ACCP did not significantly correlate with DAS28-ESR and CDAI indicating that these biomarkers are not effective in predicting the activity of RA.